- Biotron (BIT) completes recruitment of the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225
- The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatment
- Participants will receive 200 milligrams of BIT225 daily over 12 weeks to determine any changes in immune, inflammation, viral and immune activation markers
- The trial is scheduled to be completed in January 2023 with preliminary results expected in mid-2023
- Biotron is up 4.35 per cent on the market with shares trading at 4.8 cents at 2:15 pm AEDT
Biotron (BIT) has completed recruitment for the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225.
The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatment.
Participants will receive 200 milligrams of BIT225 each day over 12 consecutive weeks to determine the change in immune, inflammation, viral and immune activation markers.
The participants will be monitored four weeks prior to the study to establish the baseline levels of these markers.
The trial is scheduled to be completed in January 2023 with preliminary results expected in mid-2023.
“We are very pleased to have completed patient enrolment into this important Australian trial,” Managing Director Dr Michelle Miller said.
“The COVID-19 pandemic created an extraordinarily challenging environment in which to undertake clinical trials and our sincere thanks go to the principal investigators, trial sites and coordinators for their efforts in completing this milestone.”
Biotron was up 4.35 per cent on the market with shares trading at 4.8 cents at 2:15 pm AEDT.